Regeneron Provides Update on Biologics License Application for Odronextamab

TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters (CRLs) for the Biologics License Application...

https://www.drugs.com/nda/odronextamab_240325.html

Source: Drugs.com - New Drug Applications - March 25, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications